Wednesday, December 29, 2004
In the aftermath of Vioxx, evidence-based medicine is more important than ever
At the end of this article, there is a nice section on Lodine, which was discussed here several times:
At the end of this article, there is a nice section on Lodine, which was discussed here several times:
In undertaking its drug review, Veterans Affairs also re-examined the value of a lesser-known pain reliever, etodolac, and began using it more. The drug was first sold in 1991 as Lodine by a company that is now part of GlaxoSmithKline. Like many older medications, however, it was not extensively tested.They're currently reviewing patient records to see if Lodine has the same cardiovascular drawbacks.
A study based on a review of V.A. patient records that was published last month in a medical journal, Gastroenterology, found that the rate of stomach bleeding caused by etodolac was substantially lower than that caused by naproxen and comparable to that of Vioxx.
Posted by Kevin |
link
| Comments (1)
| 
Comments:
anecdotal[?] acute kidney failure attributed to etodolac was the unfortunate outcome of my thirty year old patient last year when his Doc [not me] did not notice his high serum creatinine as he commenced etodolac therapy for arthralgias. The patient is now on hemodialysis. The nephrologist is now very wary of NSAID's. USE WITH CAUTION, FOLLOW RENAL FUNCTION.
Post a Comment
